BioSpace

FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease

Twelve marketed drugs, including Eli Lilly’s and Novo’s weight loss mega-blockbusters, will require a label change under the new FDA update.

By BioSpace

1 min read
FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights